Yayoshi M, Araake M, Hayatsu E, Takezawa T, Yoshioka M
Microbiol Immunol. 1985;29(11):1029-37. doi: 10.1111/j.1348-0421.1985.tb00893.x.
Two attenuated strains of Mycoplasma pneumoniae, P24-S1 and P24-S11, were tested for their ability as a live vaccine to confer on hamsters immune resistance against challenge infection with a virulent strain of M. pneumoniae, FH-P24. Fifty percent protection was obtained by vaccination with the P24-S1 strain administered once or twice. In contrast, only 10% of the animals were protected by the P24-S11 vaccine even when it was given three times. Vaccination with the P24-S1 strain resulted in higher humoral and cellular immune responses than the P24-S11 did. These results suggest that the P24-S1 strain has the primary qualities a vaccine which may be used for protection against human mycoplasmal infection.
对两株减毒肺炎支原体菌株P24-S1和P24-S11进行了测试,以评估它们作为活疫苗使仓鼠获得针对强毒肺炎支原体菌株FH-P24攻击感染的免疫抵抗力的能力。单次或两次接种P24-S1菌株可使50%的仓鼠获得保护。相比之下,即使三次接种P24-S11疫苗,也只有10%的动物得到保护。接种P24-S1菌株比接种P24-S11菌株产生更高的体液免疫和细胞免疫反应。这些结果表明,P24-S1菌株具备可用于预防人类支原体感染的疫苗的主要特性。